Bleomycin for Head and Neck Venolymphatic Malformations: A Systematic Review
- 17 August 2020
- journal article
- review article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 48 (3) , 365-371
Abstract
Background: Venolymphatic malformations are rare benign vascular lesions of the head and neck. Sclerotherapy has become the first-line therapy of these lesions with bleomycin being a sclerosing agent commonly used.Purpose: To perform a systematic review of the published literature to synthesize evidence on the safety and efficacy of bleomycin for the treatment of head and neck venolymphatic malformations.Data sources: A systematic review of the literature (January 1995–May 2019) was performed in PubMed, Embase, and Cochrane Library databases to identify studies on sclerotherapy of venolymphatic malformations of the head and neck.Study selection: A total of 32 studies with participants met the inclusion criteria among which 1121 patients were included in the systematic review.Data analysis: Two reviewers independently screened and extracted data and assessed the risk of bias. The primary outcome was the subjective or objective reduction of lesion size as well as minor and major complications.Data synthesis: The bleomycin/pingyangmycin sclerotherapy achieved subjective or objective lesion size reduction in 96.3% (95% CI 94.1%–98.5%) of patients. Minor complications were observed in 16.2% and major complications in 1.1%.Conclusion: Bleomycin is a highly effective treatment of venolymphatic malformations of the head and neck with a low rate of major adverse events. This study represents an update on the “available” evidence, but only low-to-moderate quality studies were available.Limitations: This study reviewed 32 studies performed in different parts of the world, but there was heterogeneity of the study designs and interventions.Keywords
This publication has 49 references indexed in Scilit:
- Comparative Analysis of Intralesional Sclerotherapy with Sodium Tetradecyl Sulfate Versus Bleomycin in the Management of Low Flow Craniofacial Soft Tissue Vascular LesionsJournal of Maxillofacial and Oral Surgery, 2011
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)Journal of Clinical Epidemiology, 2011
- Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformationsJournal of Vascular Surgery, 2011
- Sclerotherapy with bleomycin does not adversely affect facial nerve function in children with cervicofacial cystic lymphatic malformationJournal of Pediatric Surgery, 2010
- A clinical study of ultrasound-guided intralesional injection of bleomycin A5 on venous malformation in cervical-facial region in ChinaJournal of Vascular Surgery, 2010
- Percutaneous Sclerotherapy for Facial Venous Malformations: Subjective Clinical and Objective MR Imaging Follow-Up ResultsAmerican Journal of Neuroradiology, 2009
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Bleomycin and the skinBritish Journal of Dermatology, 2006
- Local Bleomycin Injection in the Treatment of LymphangiomaEuropean Journal of Pediatric Surgery, 2005
- Grading quality of evidence and strength of recommendationsBMJ, 2004